EP1789451A4 - TIE COMPLEX BINDING PROTEINS - Google Patents
TIE COMPLEX BINDING PROTEINSInfo
- Publication number
- EP1789451A4 EP1789451A4 EP05784935A EP05784935A EP1789451A4 EP 1789451 A4 EP1789451 A4 EP 1789451A4 EP 05784935 A EP05784935 A EP 05784935A EP 05784935 A EP05784935 A EP 05784935A EP 1789451 A4 EP1789451 A4 EP 1789451A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- binding proteins
- complex binding
- tie complex
- tie
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/026116 WO2005019267A2 (en) | 2003-08-12 | 2004-08-12 | Tie1-binding ligands |
US10/916,840 US7348001B2 (en) | 2003-08-12 | 2004-08-12 | Tie1-binding ligands |
US11/049,536 US7871610B2 (en) | 2003-08-12 | 2005-02-02 | Antibodies to Tie1 ectodomain |
PCT/US2005/028413 WO2006020706A2 (en) | 2004-08-12 | 2005-08-09 | Tie complex binding proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1789451A2 EP1789451A2 (en) | 2007-05-30 |
EP1789451A4 true EP1789451A4 (en) | 2009-12-02 |
Family
ID=35908119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05784935A Withdrawn EP1789451A4 (en) | 2004-08-12 | 2005-08-09 | TIE COMPLEX BINDING PROTEINS |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1789451A4 (ja) |
JP (1) | JP2008532476A (ja) |
AU (1) | AU2005272848A1 (ja) |
CA (1) | CA2576886A1 (ja) |
WO (1) | WO2006020706A2 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EP2374887A3 (en) | 2005-03-25 | 2012-07-18 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
US20090215165A1 (en) | 2005-05-20 | 2009-08-27 | James Rance | High-level expression of recombinant antibody in a mammalian host cell |
AU2006332713B2 (en) | 2005-12-30 | 2013-01-17 | Takeda Pharmaceutical Company Limited | Metalloproteinase binding proteins |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
JP2009532027A (ja) | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗igf−1r抗体およびその使用 |
BRPI0717760A2 (pt) * | 2006-10-17 | 2013-11-12 | Dyax Corp | Métodos para tratar um distúrbio relacionados à angiogênese, para prover uma terapia adjuvante pós-operatória, para sensibilizar a vasculatura tumoral a um decréscimo no vegf, para inibir o recrescimento tumoral em um indivíduo e para reduzir a freqüência de administração do agente de quimioterapia ou da radiação a um indivíduo, e, kit |
PT2716301T (pt) * | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
EP2036980A1 (de) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
BRPI0821906B1 (pt) | 2008-01-03 | 2022-06-07 | The Scripps Research Institute | Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
UA104868C2 (uk) | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
CA2748158A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
ES2694411T3 (es) * | 2011-08-19 | 2018-12-20 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-Tie2 y usos de los mismos |
CN105451767B (zh) | 2013-03-15 | 2019-10-18 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
EP3081575A1 (en) * | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
CN117083305A (zh) * | 2021-03-25 | 2023-11-17 | 南京金斯瑞生物科技有限公司 | 抗体融合蛋白及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955291A (en) * | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
WO2005019267A2 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365154B1 (en) * | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
-
2005
- 2005-08-09 AU AU2005272848A patent/AU2005272848A1/en not_active Abandoned
- 2005-08-09 CA CA002576886A patent/CA2576886A1/en not_active Abandoned
- 2005-08-09 EP EP05784935A patent/EP1789451A4/en not_active Withdrawn
- 2005-08-09 JP JP2007525760A patent/JP2008532476A/ja not_active Withdrawn
- 2005-08-09 WO PCT/US2005/028413 patent/WO2006020706A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955291A (en) * | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
WO2005019267A2 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
Non-Patent Citations (5)
Title |
---|
DRANSFIELD: "Targeting tie1 inhibits the growth of tumor xenografts as a monotherapy and has increased activity in combination with a VEGF inhibitor", EUROPEAN JOURNAL OF CANCER SUPPLEMENTS, vol. 4, no. 12, 28 September 2004 (2004-09-28), XP002550532, Retrieved from the Internet <URL:http://ex2.excerptamedica.com/ciw-04ena/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=huang&topicselected=*&selection=ABSTRACT&qryStartRowDetail=1> [retrieved on 20091014] * |
JOSTOCK T ET AL: "Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 289, no. 1-2, 1 June 2004 (2004-06-01), pages 65 - 80, XP004520880, ISSN: 0022-1759 * |
SIEMEISTER G ET AL: "TWO INDEPENDENT MECHANISMS ESSENTIAL FOR TUMOR ANGIOGENESIS: INHIBITION OF HUMAN MELANOMA XENOGRAFT GROWTH BY INTERFERING WITH EITHER THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PATHWAY OR THE TIE-2 PATHWAY", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 59, no. 13, 1 July 1999 (1999-07-01), pages 3185 - 3191, XP000971187, ISSN: 0008-5472 * |
STEUKERS M ET AL: "Rapid kinetic-based screening of human Fab fragments", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 310, no. 1-2, 20 March 2006 (2006-03-20), pages 126 - 135, XP025158202, ISSN: 0022-1759, [retrieved on 20060320] * |
TAKAGI HITOSHI ET AL: "Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JAN 2003, vol. 44, no. 1, January 2003 (2003-01-01), pages 393 - 402, XP002550533, ISSN: 0146-0404 * |
Also Published As
Publication number | Publication date |
---|---|
EP1789451A2 (en) | 2007-05-30 |
AU2005272848A2 (en) | 2006-02-23 |
WO2006020706A2 (en) | 2006-02-23 |
AU2005272848A1 (en) | 2006-02-23 |
WO2006020706A3 (en) | 2006-10-12 |
CA2576886A1 (en) | 2006-02-23 |
JP2008532476A (ja) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1789451A4 (en) | TIE COMPLEX BINDING PROTEINS | |
IL181005A0 (en) | Polypeptide comprising binding domains | |
ZA200702004B (en) | Binding domain fusion proteins | |
HK1103747A1 (en) | Immunoglobulin binding hosm | |
ZA200703445B (en) | Nanoparticulated whey proteins | |
IL182279A0 (en) | Angiopoietin-2-specific binding agents | |
IL188671A0 (en) | Il-6 binding proteins | |
GB0404187D0 (en) | Binding agents | |
GB0423974D0 (en) | Proteins | |
GB0410627D0 (en) | Specific binding members | |
GB0417887D0 (en) | Protein | |
GB0511799D0 (en) | Protein binding ligands | |
GB0401882D0 (en) | Protein | |
GB0416035D0 (en) | Protein | |
GB0405643D0 (en) | Proteins | |
GB0412570D0 (en) | Proteins | |
GB0411678D0 (en) | Proteins | |
GB0405885D0 (en) | Proteins | |
GB0415161D0 (en) | Proteins | |
GB0423002D0 (en) | Proteins | |
GB0418666D0 (en) | Proteins | |
GB0418248D0 (en) | Proteins | |
GB0408665D0 (en) | Protein | |
GB0414086D0 (en) | Protein | |
GB0413604D0 (en) | Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070308 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HOET, RENE Inventor name: PIETERS, HENK Inventor name: WOOD, CLIVE R. Inventor name: HUFTON, SIMON E. Inventor name: DRANSFIELD, DANIEL T. |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1105646 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 21/04 20060101ALI20091022BHEP Ipc: C07K 16/28 20060101ALI20091022BHEP Ipc: A61P 35/00 20060101ALI20091022BHEP Ipc: A61K 39/395 20060101AFI20091022BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20091102 |
|
17Q | First examination report despatched |
Effective date: 20100303 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110510 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1105646 Country of ref document: HK |